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Objective: Endovascular stents are accepted therapy for iliac artery stenoses and occlusions. Surgery is the recommended
therapy for patients with severe iliac artery disease, including those with the combination of ipsilateral common iliac
artery (CIA) and external iliac artery (EIA) stenoses/occlusions. This study compared patient outcomes, including late
open conversion rates, for combined ipsilateral CIA and EIA stenting vs CIA or EIA stents alone.
Methods: Between 1998 and 2010, 588 patients underwent iliac artery stenting at two institutions. Patient comorbidities
and outcomes were retrospectively reviewed, and analyses were performed using multivariate regression and Kaplan-
Meier methods.
Results: There were 436 extremities with CIA stents, 195 with EIA stents, and 157 with CIA and EIA stents. The groups
did not differ significantly in demographics, comorbidities, or treatment indications. During follow-up, 183 patients
died, 95 underwent an endovascular reintervention, and 48 required late open conversion. For patients in the CIA or EIA
stent group, the mean  standard error survival was 5.3  0.3 years, secondary endovascular intervention-free survival
was 7.4  0.6 years, late open conversion-free survival was 9.8  0.4 years, and amputation-free survival was 7.6  0.4
years. In the CIA and EIA stent group, survival was 6.1  0.6 years, secondary endovascular intervention-free survival
was 7.2  0.6 years, late open conversion-free survival was 9.0  1.1 years, and amputation-free survival was 8.4  0.5
years. Survival, reintervention-free survival, late open conversion-free survival, and amputation-free survival were all
similar between patient groups (all P > .05). CIA and EIA stenting in combination was not a predictor of death,
reintervention, late open conversion, or amputation.
Conclusions: Outcomes are similar for patients with CIA or EIA stents and for those with combined ipsilateral CIA and
EIA stents. Late open conversions for iliac artery stent failure are uncommon and not influenced by the location or extent
of prior iliac artery stent placement. Endovascular therapy for aortoiliac disease should be extended to consider selected
patients with ipsilateral CIA and EIA stenoses/occlusions. ( J Vasc Surg 2012;55:1637-46.)
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fEndovascular therapy is the primary treatment of symp-
tomatic aortoiliac occlusive disease (AIOD). With properly
selected lesions, 70% to 79% primary patency at 5 years can
be achieved with iliac artery percutaneous transluminal
angioplasty and stenting (PTAS). Conversely, poor-quality
run-off vessels, severity of ischemia, longer treated seg-
ments, diabetes, renal failure, tobacco use, and female sex
have been associated with increased failure rates of endo-
vascular treatment.1-6
Operative management of advanced AIOD lesions is
currently recommended. Advanced AIOD lesions encom-
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doi:10.1016/j.jvs.2011.12.048ass a variety of aortoiliac disease patterns, some of which
ay actually be well treated with endovascular therapies.
reatment of selected advanced AIOD lesions with PTAS
as resulted in primary patency rates of 69% to 85%.7-9
herefore, percutaneous treatment for some advanced
IOD lesions may be appropriate. One category of ad-
anced AIOD includes combined common (CIA) and ex-
ernal iliac artery (EIA) disease, and many of these lesions
re amenable to endovascular therapy.
An “endovascular first” approach for combined CIA
nd EIA lesions can be justified if patient-centered results
re reasonable and failures do not lead to adverse patient
utcomes such as death, limb loss, repeat endovascular
nterventions, or high rates of late open conversions for
ailed endovascular treatment. This study, therefore, evalu-
ted patient outcomes for endovascular treatment of com-
ined ipsilateral CIA and EIA disease. We compared these
esults to control patients with treatment limited to the
IA or EIA alone.
ETHODS
This study was approved by the Institutional Review
oard (IRB) at the Portland Department of Veterans Af-
airs (VA) Medical Center (PVAMC, IRB study No. 2452)
nd by the IRB at Oregon Health & Science University
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ments were exempt from this study.
Patients. Device implantation records at the PVAMC
and OHSU Hospital were used to create a list of 588
patients who underwent successful PTAS procedures for
AIOD from January 1998 through March 2010. Patients
whose procedures failed and those who had an iliac artery
procedure as an adjunct to an aortic endograft were ex-
cluded.
Demographics captured included sex and age. Comor-
bidities assessed were coronary artery disease (CAD), dia-
betes mellitus (DM), hypertension, hyperlipidemia, history
of tobacco use, end-stage renal disease requiring hemodi-
alysis, and chronic renal insufficiency, defined as creatinine
 1.5 mg/dL. Patients were defined as having CAD if they
had a history of myocardial infarction, coronary artery
bypass grafting, or stenting. CAD, DM, hypertension, and
hyperlipidemia were also considered to be comorbidities if
they were listed in the medical history at the initial presen-
tation. Patients with a positive tobacco history were either
currently smoking at the time of initial presentation or had
quit smoking 10 years of the initial presentation. Medi-
cations assessed included aspirin, warfarin, -blockers,
clopidogrel, and statins. Indications for PTAS, such as
claudication, rest pain, or tissue loss, in addition to ankle-
brachial indexes (ABIs) were also recorded.
Procedures. Procedural information collected with
respect to initial PTAS included the location of stent place-
ment and the diameters of stents placed in each artery. For
the purposes of this study, patients were placed into the
CIA or EIA stent group if stents were placed into the CIA
or the EIA, but not both. Patients with stents placed in
both the ipsilateral CIA and EIA were placed in the CIA
and EIA stent group.
Self-expanding and balloon-expandable stents were
used. Kissing stent placement was noted. Concomitant
ipsilateral infrainguinal operations were also recorded and
were defined as adjunct operations performed during the
same hospitalization, including major amputations, minor
amputations, common femoral artery reconstructions, pro-
fundaplasty, or lower extremity bypass.
During follow-up, secondary ipsilateral endovascular
interventions after failed initial PTAS were recorded. Pro-
cedural information was collected as with the primary in-
tervention. Concomitant operations performed in associa-
tion with secondary endovascular procedures were also
recorded. Late open conversions (aortobifemoral, axillo-
bifemoral, femorofemoral) to treat iliac stent failure as well
as ipsilateral concomitant procedures as defined above were
recorded.
Complications in the immediate postprocedural pe-
riod, after the initial PTAS, a secondary endovascular inter-
vention, or a late open conversion, were assessed and
included hematoma (local or retroperitoneal), arterial per-
foration (after PTAS), distal embolization, acute myocar-
dial infarction, acute renal failure (creatinine increase0.5
mg/dL), or unplanned postprocedure intensive care unit tdmission. Interventions for complications were also re-
orded.
Follow-up. Follow-up was annual and included ABI
easurement and a physical examination. Information re-
arding claudication, rest pain, or tissue loss was also re-
orded.
Data analysis. Univariate analyses of variables were
erformed using the Pearson 2 test or the Fisher exact test
when n  10) for categoric variables and independent t
ests for continuous variables. Survival, secondary endovas-
ular intervention-free survival, late open conversion-free
urvival, and amputation-free survival were calculated using
he Kaplan-Meier method. The log-rank test (Mantel-Cox)
as used to compare patient outcomes for patients treated
ith CIA or EIA stents and with those treated with CIA
nd EIA stents. Multivariate analyses of variables affecting
atient outcomes were performed using Cox regression
odeling. Variables were entered into the model using the
orced entry method. All statistical analyses were performed
sing SPSS 19 software (IBM Corp, Somers, NY). Mean
ata are presented with the standard deviation. Values of
 .05 were considered significant.
ESULTS
Patient characteristics. Mean patient age at time of
nitial PTAS was 63.3  9.9 years. There were 530 men
90.1%) and 58 women (9.9%), in whom 436 extremities
ere treated with CIA stents, 195 extremities were treated
ith EIA stents, and 157 extremities were treated with CIA
nd EIA stents. Comorbidities, medications, and indication
or treatment at the time of PTAS for both patient groups
re reported in Table I and in Supplementary Table I,A and
(online only). Most patients in both groups had CAD,
ypertension, and a positive tobacco history. Most were
aking aspirin before PTAS, and 52% reported claudication
ymptoms before PTAS (Table I).
Comparison of patients with CIA or EIA stents vs
atients with CIA and EIA stents. Demographics, co-
orbidities, medications, and indications for initial PTAS
f patients with CIA or EIA stents and patients with CIA
nd EIA stents in combination were compared (Table I).
atients treated with ipsilateral CIA and EIA stents were
rescribed aspirin more frequently before PTAS than pa-
ients treated with CIA or EIA stents (73.8% vs 60.2%; P
01). All other clinical characteristics were similar between
he two groups (Table I).
Outcome for ankle-brachial index. Mean changes in
BI after primary PTAS, secondary endovascular interven-
ion, and late open conversion are reported in Table II.
here was no significant difference in ABI improvement
hen the CIA or EIA stent group was compared with the
IA and EIA stent group (P  .05 for all; Table II).
A total of 206 patients who presented with claudication
efore the initial PTAS had complete information regard-
ng their symptoms at the time of follow-up. The mean ABI
mprovement for the 110 patients (53.3%) whose claudica-
ion symptoms resolved after PTAS was 0.18  0.20, and
he mean ABI change for the 96 patients (46.6%) with
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Volume 55, Number 6 Danczyk et al 1639persistent exercise-associated leg pain after PTAS was
0.07  0.22 (P  .03). There was no association between
the location of stents placed and resolution of claudication
symptoms. Of those patients with CIA or EIA stents, 54.5%
experienced resolution of their claudication symptoms and
45.5% continued to have exercise-associated leg pain after
PTAS. In the CIA and EIA stent group, 50% experienced
resolution of claudication while the remaining patients
continued to have exercise-associated leg pain (P  .63).
Clinical outcomes. After PTAS in the CIA or EIA
stent group, 95 patients (21.3%) were lost to follow-up,
141 (31.5%) died, 75 (16.8%) required secondary endovas-
cular intervention, 36 (8.1%) required late open conversion
for failed endovascular intervention, and 11 (2.5%) re-
quired major amputation (transtibial or transfemoral). Af-
ter PTAS in the CIA and EIA stent group, 27 patients
(19.1%) were lost to follow-up, 42 (29.8%) died, 20
(14.2%) required secondary endovascular intervention, 12
(8.5%) required late open conversion, and seven (4.9%)
required major amputation. There were no significant dif-
ferences in the number of patients who were lost to follow-
up, died, required secondary endovascular intervention or
late open conversion, or underwent amputation between
the CIA or EIA stent patients and the CIA and EIA stent
patients (P  .21 for all; Table III and Supplementary
Table I. Clinical characteristics of patient groups
Variablesa
CIA or EIA stent
(n  447)
CIA and EIA stent
(n  141) P
Age, years 63.6  9.5 64.1  10.4 .58
Female sex 50 (11.2) 8 (5.7) .07
Comorbidities
CAD 275 (61.5) 100 (70.9) .05
DM 166 (37.1) 58 (41.1) .43
Hypertension 359 (80.3) 117 (83.0) .54
Hyperlipidemia 282 (63.1) 93 (66.0) .55
CRI 60 (13.4) 13 (9.2) .24
Hemodialysis 14 (3.1) 3 (2.1) .77
Tobacco history 403 (90.2) 133 (94.3) .17
Medications
Aspirin 269 (60.2) 104 (73.8) .01b
Warfarin 35 (7.8) 9 (6.4) .71
-Blocker 232 (51.9) 76 (53.9) .70
Clopidogrel 36 (8.1) 8 (5.7) .46
Statin 258 (57.7 81 (57.4) .99
Indication
Claudication 233 (52.1) 74 (52.5) .92
CLI 206 (46.1) 67 (47.5) .92
Rest pain 67 (15.0) 28 (19.9) .24
Gangrene 37 (8.3) 11 (7.8) .99
Ulcer 60 (13.4) 18 (12.8) .89
Acute ischemia 31 (6.9) 8 (5.7) .70
Unknown 8 (1.0) 0 (0.0) .99
CAD, Coronary artery disease; CIA, common iliac artery; CLI, critical limb
ischemia; CRI, chronic renal insufficiency (creatinine 1.5 mg/dL); DM,
diabetes mellitus; EIA, external iliac artery.
aContinuous data are expressed as the mean standard deviation; categoric
data are expressed as number (%).
bStatistically significant (P  .05), 2 test/Fisher exact test.Table II, A and B, online only). oOf the 95 patients who required a secondary endovas-
ular intervention, 49 reinterventions were performed to
pecifically address in-stent restenosis. There were 34 in-
tent revisions in the CIA or EIA stent group and 15
n-stent revisions in the CIA and EIA stent group (P 
49).
Most patients who underwent late open conversion
ere treated with aortobifemoral bypass. Of the 36 patients
n the CIA or EIA stent group who underwent late open
onversion, 25 underwent aortobifemoral bypasses, three
nderwent axillobifemoral bypasses, and eight underwent
emorofemoral bypasses. Of the 12 patients in the CIA and
IA stent group who underwent late open conversion,
ight underwent aortobifemoral bypasses, three had axillo-
ifemoral bypasses, and one underwent femorofemoral by-
ass. The data show that most of the bypasses performed in
oth groups were aortobifemoral bypasses (P  .02).
For patients in the CIA or EIA stent group, mean
urvival was 5.33  0.3 years, secondary endovascular
ntervention-free survival was 7.44  0.6 years, late open
onversion-free survival was 9.88  0.44 years, and
mputation-free survival was 7.6  0.4 years. For patients
n the CIA and EIA stent group, mean survival was 6.1 
.6 years, secondary endovascular intervention-free survival
as 7.2  0.6 years, late open conversion-free survival was
.0 1.1 years, and amputation-free survival was 8.4 0.5
ears. There was no difference in survival, secondary endo-
ascular reintervention-free survival, late open conversion-
ree survival, or amputation-free survival between the CIA
r EIA stent patients and CIA and EIA stent patients (Figs
-3, data not shown for amputation-free survival).
Univariate analysis. Univariate analyses of demo-
raphic variables, comorbidities, medications, indications
or primary intervention, and location of stent placement
CIA or EIA, CIA and EIA) were performed for all out-
omes, including death, secondary endovascular interven-
ion, late open conversion, and amputation (Table IV,
mputation data not shown, and Supplementary Table III,
and B, online only). In addition, univariate analyses of
tent diameter and the use of kissing stents were performed.
Variables associated with mortality included male sex,
AD, DM, hypertension, chronic renal insufficiency, he-
odialysis, the use of warfarin, and critical limb ischemia
CLI) as an indication for intervention. Tobacco use was
ssociated with death; however, 536 patients (91.1%) had a
ignificant history of tobacco use. Location of stent place-
ent was not associated with death.
The only variable associated with the need for second-
ry endovascular intervention was tobacco history: 93 pa-
ients (97.9%) had a positive tobacco history compared
ith two patients (2.1%) who were nonsmokers (P .01).
Variables associated with late open conversion included
ale sex, hypertension, and acute ischemia (P .05 for
ll). Seven patients (14.6%) undergoing late open conver-
ion presented with acute ischemia compared with 41
85.4%) who presented with claudication or CLI (P .03).
o other variables were associated with the need for late
pen conversion, including the location of stents placed at
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amputation was CLI as an indication for the procedure
(P  .01, data not shown). Neither stent diameter nor the
use of kissing stents was associated with death, the need for
secondary endovascular intervention or late open conver-
sion, or amputation (P  .20 for all, data not shown).
Cox regression analysis. Cox regression analysis was
performed for clinical outcomes, including death, second-
ary endovascular intervention, and late open conversion.
Cox regression analysis was not performed for amputation
because only 18 patients required amputation. Variables
significantly associated with outcomes (P  .05) after uni-
variate analysis were included in the regression model (Ta-
ble V and Supplementary Table IV, A and B, online only).
CAD and CLI were associated with decreased survival,
with hazard ratios (HRs) of 1.84 and 1.91, respectively
(P  .01 for all). Tobacco history was associated with
increased survival (HR, 0.56; P  .02) and with decreased
reintervention-free survival (HR, 5.15; P  .03). No vari-
ables were identified as independent predictors of the need
for late open conversion (P  .05 for all).
Concomitant operations. At the time of the initial
PTAS, 102 patients (17.3%) underwent a concomitant
operation, including lower extremity bypass in 44, femoral
artery reconstruction in 29, femorofemoral bypass in seven,
and profundaplasty in eight. The remaining procedures
included four digital amputations, two major amputations,
and one superficial artery angioplasty.
After secondary endovascular intervention, 79 patients
(83.2%) underwent a concomitant operation, including
Table II. Comparison of mean changes in ankle-brachial i
Variable
CIA or EIA stent
Mean ABI SD (95%
Primary PTAS 0.13 0.23 (0.11
SEI 0.15 0.26 (0.11
Late open conversion 0.21 0.33 (0.11
CI, Confidence interval; CIA, common iliac artery; EIA, external iliac a
deviation; SEI, secondary endovascular intervention.
aIndependent t test.
Table III. Clinical outcomes of common iliac artery
(CIA) or external iliac artery (EIA) stent vs CIA and EIA
stent groups
Outcome
CIA or EIA stent
(n  447)
No. (%)
CIA and EIA stent
(n  141)
No. (%) Pa
Lost to follow-up 95 (21.3) 27 (19.1) .21
Death 141 (31.5) 42 (29.8) .76
SEI 75 (16.8) 20 (14.2) .51
Late open conversion 36 (8.1) 12 (8.5) .86
Amputation 11 (2.5) 7 (4.9) .25
SEI, Secondary endovascular intervention.
a2 test, Fisher exact test.lower extremity bypass in 37, femoral artery reconstruction an 25, femorofemoral bypass in 11, or profundaplasty in
our.
At the time of late open conversion for failure of an
ortoiliac catheter-based intervention, four patients (8.3%)
nderwent concomitant operations, comprising femoral
rtery reconstruction in two and lower extremity bypass in
wo.
For each of the clinical outcomes assessed, no differ-
nce was seen in the number of patients undergoing con-
omitant operations between the CIA or EIA stent group
nd the CIA and EIA stent group (P  .23 for all). In
ddition, a second analysis was performed excluding the 97
atients who underwent concomitant operations. The re-
ults of this secondary analysis did not change the results of
he study (data not shown).
Complications. After PTAS, 46 (7.8%) complications
ere recorded. Hematoma accounted for 21 complica-
ions, with two of these retroperitoneal. Nine patients had
n arterial dissection (seven EIA, two CIA), distal emboli
ccurred in five (one required embolectomy), three stayed
vernight in the surgical intensive care unit, two patients
ad a rise in serum creatinine0.5 mg/dL, one patient had
cute myocardial infarction, one experienced congestive
eart failure exacerbation, one had a pulmonary embolism,
nd one experienced a vasovagal episode. One patient died
f a retroperitoneal hemorrhage associated with the initial
TAS.
After secondary endovascular intervention, eight (8.4%)
omplications were recorded. Hematoma accounted for two
omplications, distal emboli occurred in two, two had a rise in
reatinine0.5 mg/dL, one patient had an acute myocardial
nfarction, one patient had a stroke, and mesenteric ischemia
n 1 patient required exploratory laparotomy with small bowel
esection and an extended intensive care unit stay. No deaths
ere associated with secondary endovascular interventions.
No complications or deaths, as defined above, were
ssociated with late open conversion.
For each of the above clinical outcomes, no difference
as seen between the number of complications experienced
y patients in the CIA or EIA stent group and the CIA and
IA stent group (P  .34 for all).
ISCUSSION
Endovascular intervention is accepted therapy for many
atterns of symptomatic AIOD. Although operative man-
(ABI) after revascularization procedure by group
CIA and EIA stent
PaMean ABI SD (95% CI)
) .17 0.23 (0.13-0.21) .06
) .14 0.22 (0.08-0.19) .62
) .32 0.34 (0.16-0.48) .23
PTAS, percutaneous transarterial angioplasty and stenting; SD, standardndex
CI)
-0.15
-0.20
-0.31
rtery;gement is recommended for advanced AIOD lesions,
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Volume 55, Number 6 Danczyk et al 1641these lesions encompass many different patterns of disease,
some of which are amenable to rather straightforward
endovascular interventions.
Endovascular treatment of EIA lesions has also been
questioned,10-13 and by implication, treatment of a com-
bination of ipsilateral EIA and CIA lesions may be asso-
ciated with poorer results than treatment of isolated CIA
Fig 1. Kaplan-Meier analysis showed survival was simi
artery (EIA) stent group and the CIA and EIA stent groor EIA lesions. However, few reports have focused on wesults of endovascular treatment of ipsilateral CIA and
IA lesions.
This study focused on patient-centered outcomes of
ndovascular therapy of CIA and EIA occlusive lesions and
ot on patency. Although patency is important in the
valuation of new technologies, iliac artery stenting is
learly not new technology, and many of our VA patients
tween the common iliac artery (CIA) or external iliac
 .38, log-rank test).lar beere not monitored with serial imaging studies of the
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patient-oriented outcomes such as morbidity and need for
further interventions. This approach, although not ideal, is
in line with the recent orientation of the U.S. Food and
Drug Administration, where patient-centered outcomes,
such as need for reintervention and not patency, are con-
sidered the primary end points for evaluation of endovas-
cular technology.14
Irrespective of patency, for an endovascular-first approach
to a combination of CIA and EIA lesions to be reasonable
there must, at a minimum, be acceptable initial outcomes of
Fig 2. Kaplan-Meier analysis showed reintervention-fre
or external iliac artery (EIA) stent group and the CIA ansuch procedures, a limited need for reintervention, and no ancreased severity of the consequences of late failures. Our
ata, the largest series to date of endovascular treatment of
ombined treatment of CIA and EIA lesions,15,16 therefore
upports, from the patient perspective, combined endovascu-
ar treatment of selected ipsilateral CIA and EIA occlusive
esions. By analyzing patients with isolated EIA or CIA lesions
s the control group, we found no differences in complica-
ions, improvement in ABI, survival, limb salvage, and need
or time to reintervention or need for late open conversion in
atients treated with catheter-based techniques for isolated
IA or EIA disease vs those treated for a combination of CIA
ival was similar between the common iliac artery (CIA)
A stent group (P  .23, log-rank test).e survnd EIA disease.
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Volume 55, Number 6 Danczyk et al 1643Our data for durability of combination treatment of
ipsilateral EIA and CIA lesions is consistent with that
reported by others for isolated EIA and isolated CIA occlu-
sive lesions treated with endovascular techniques.3,17 This
justifies categorizing patients treated for isolated EIA and
CIA arteries as the “control group” in evaluating combined
treatment of ipsilateral CIA and EIA disease.
The combination of CIA and EIA stent placement is
essentially a surrogate for length of diseased artery treated.
The data here, therefore, may suggest the length of diseased
artery treated endovascularly in the iliac artery position is less
important than generally believed if stents are routinely used
Fig 3. Kaplan-Meier analysis showed that late open co
artery (CIA) or external iliac artery (EIA) stent group anin the iliac arteries, as prior studies indicating increased length Ef diseased segment treated portended poorer outcomes were
ased on selective rather than routine stenting.13,18
Failure of a prosthetic infrainguinal graft or an infrain-
uinal catheter-based procedure may lead to deterioration
f the patient’s prospects of subsequent operative interven-
ion.19,20 Our data with respect to AIOD, however, indi-
ate late open conversion for failed PTAS of AIOD is
nfrequently required, and there seem to be no differences
n the rate or types of subsequent open operative proce-
ures required for failure of endovascular treatment of
IOD, regardless if the patient was initially treated for an
solated iliac lesion or a combination of ipsilateral CIA and
ion-free survival was similar between the common iliac
CIA and EIA stent group (P  .96, log-rank test).nversIA lesions.
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curred in patients in this series who underwent late open
conversion for failed endovascular treatment of AIOD.
Table IV. Univariate analysis of death, secondary endovas
Variablesa
Death
(n  183) P
Age at PTAS,
years
66.9  8.5
Female sex 8 (4.4) .01b
Comorbidities
CAD 138 (75.4) .01b
DM 85 (46.4) .03b
Hypertension 159 (86.9) .02b
Hyperlipidemia 113 (61.7) .52
CRI 38 (20.8) .01b
Hemodialysis 11 (6.0) .01b
Tobacco history 159 (86.9) .02b
Medication
Aspirin 120 (65.6) .52
Warfarin 20 (10.9) .04b
-Blocker 101 (55.2) .37
Clopidogrel 11 (6.0) .40
Statin 96 (52.5) .09
Indication
CLI 114 (62.3) .01b
Acute ischemia 14 (7.7) .59
Stent location
CIA or EIA 141 (77.0) .76
CIA and EIA 42 (23.0)
CAD, Coronary artery disease; CIA, common iliac artery; CLI, critical limb i
mellitus; EIA, external iliac artery; PTAS, percutaneous transarterial angiop
aContinuous data are presented as mean  standard deviation; categoric da
bStatistically significant (P  .05), 2 test/Fisher exact test.
Table V. Cox regression of death, secondary endovascular
Variable
Death (n  183)
HR (95% CI) P
Female sex 0.59 (0.29-1.23 .16
Comorbidities
CAD 1.84 (1.21-2.72) .01a
DM 1.29 (0.93-1.78) .12
Hypertension 1.16 (0.70-1.92) .58
Hyperlipidemia 1.01 (0.66-1.53) .97
Tobacco history 0.56 (0.35-(0.90) .02a
Medication
Aspirin 1.30 (0.93-1.82) .13
-Blocker 1.00 (0.71-1.40) .99
Statin 0.66 (0.44-0.99) .05
Indication
CLI 1.91 (1.38-2.64) .01a
Stent location
CIA and EIA 0.80 (0.56-1.14) .22
CAD, Coronary artery disease; CI, confidence interval; CIA, common iliac a
HR, hazard ratio; SEI, secondary endovascular intervention.
aStatistically significant (P  .05), forced entry.This may partly reflect the small numbers of patients sequiring late open conversion. In addition, the long
ime from the initial endovascular treatment to late open
onversion, as well as compliance with follow-up, may
intervention, and late open conversion
Outcome
SEI Late open conversion
(n  95) P (n  48) P
9.8  8.1 57.2  8.8
12 (12.6) .35 9 (18.8) .04b
61 (64.2) .99 31 (64.6) .99
31 (32.6) .25 12 (25.0) .06
72 (75.8) .20 32 (66.7) .01b
57 (60.0) .42 29 (60.4) .64
6 (6.3) .06 2 (4.2) .11
1 (1.1) .33 1 (2.1) .99
93 (97.9) .01b 44 (91.7) .99
55 (57.9) .25 34 (70.8) .35
3 (3.2) .09 1 (2.1) .25
49 (51.6) .91 21 (43.8) .23
9 (9.5) .40 2 (4.2) .57
55 (57.9) .99 26 (54.2) .65
37 (38.9) .42 19 (39.6) .36
6 (6.3) .99 7 (14.6) .03b
75 (78.9) .51 36 (75.0) .86
20 (21.1) 12 (25.0)
ia; CRI, chronic renal insufficiency (creatinine1.5 mg/dL); DM, diabetes
nd stenting; SEI, secondary endovascular intervention.
umber (%).
rvention, and late open conversion
Outcome
SEI (n  95)
Late open conversion
(n  48)
R (95% CI) P HR (95% CI) P
1 (0.85-3.07) .15 1.49 (0.67-3.33) .33
2 (0.74-2.01) .43 1.98 (0.97-4.07) .06
0 (0.50-1.30) .37 0.55 (0.27-1.11) .10
6 (0.47-1.57) .62 0.48 (0.22-1.06) .07
8 (0.37-1.23) .20 0.87 (0.39-1.94) .74
5 (1.18-22.48) .03a 0.63 (0.21-1.86) .40
3 (0.45-1.17) .19 1.64 (0.81-3.32) .17
6 (0.83-2.21) .22 1.22 (0.60-2.45) .58
8 (0.66-2.12) .57 1.01 (0.46-2.18) .99
8 (0.87-2.19) .17 1.39 (0.74-2.63) .31
8 (0.45-1.34) .37 1.06 (0.54-2.09) .87
CLI, critical limb ischemia; DM, diabetes mellitus; EIA, external iliac artery;cular
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typical patient in a larger series of open operations for
AIOD. In any case, however, patients undergoing late
conversion in this series did well, indicating the patients
were not likely harmed by their initial AIOD endovascu-
lar procedure with respect to a subsequent open proce-
dure.
We do not believe these data can be used to justify a
blanket approach to treatment of all combined ipsilateral
CIA and EIA occlusive lesions. This was a retrospective
study and patients were undoubtedly treated with some
selection bias. We continue to believe open surgery for
some patients with advanced AIOD is a very reasonable
choice for better-risk patients. The potential selection of
good-risk patients with more advanced lesions for open
surgery could bias the data in terms of decreased survival
for those treated with catheter-based techniques. Alter-
natively, there may be decreased need for reintervention
after catheter-based treatment, because potentially,
some patients with more advanced lesions that were felt
would do poorly with a catheter-based procedure were
advised to undergo open surgery.
Patients treated in this study were derived primarily
from our affiliated VA hospital (PVAMC) and demon-
strated 5-year mortality of 50% on a background of a high
prevalence of tobacco abuse, and given the long time span
of the study, less than universal use of adjunctive clo-
pidogrel with stenting. Our results, therefore, may not be
strictly extrapolated to a more community-based practice
but are unlikely to be better than those achievable in a
population of patients with less overall burden of disease.
The results presented here, therefore, should be encourag-
ing to competent endovascular practitioners in practices
with varying populations of patients to perform combined
ipsilateral CIA and EIA catheter-based procedures in se-
lected patients with combined ipsilateral CIA and EIA
occlusive disease.
CONCLUSIONS
Endovascular treatment of CIA occlusive disease or
EIA occlusive disease or a combination of ipsilateral CIA
and EIA occlusive disease results in similar patient-ori-
ented outcomes. Open conversions for iliac artery stent
failure are uncommon, occur late, and are not influenced
by the location or extent of iliac artery stent placement.
This study suggests that total endovascular management
for selected patients with combined CIA and EIA disease
is acceptable. Recommendations for therapy of AIOD
should be modified to encourage endovascular therapy
for selected patients with ipsilateral CIA and EIA steno-
ses or occlusions.
We thank Sharon Kryger for her assistance with the
patient database creation and management that was vital to
the completion of this work.UTHOR CONTRIBUTIONS
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DrMarkR.Nehler (Aurora, Colo). Dr Danczyk and colleagues
from Oregon Health & Science University present a comparison
series of either multiple vs isolated endovascular treatment with stents
in the iliac system. The procedural indications, demographics, and
comorbidities are typical of the predominately Veterans Affairs popu-
lation it represents. Of note, roughly 20% to 30% of the patients were
not on either statins or antiplatelet therapy at the time of procedure,
reflecting the 12-year time frame of the data set; both medications
would be required as background therapy in clinical trials currently.
Failure to cross the lesions was not included, making the results a bit
better than reality and the loss to follow-up was high, at 20%, also
reflecting the long duration of the study period.
Regardless of these study limitations, several points are
undeniable: 15 to 25 percentage points of the lesions treated
were TransAtlantic Inter-Society Consensus (TASC) D—more
so in the multiple iliac stent group. There was no difference in
the multiple vs isolated iliac stent group in secondary interven-
tion and salvage operation over time, both a modest 15% and
8%, respectively. As such, this paper joins others that have
demonstrated that a large number of TASC D iliac lesions can
be treated successfully with an endovascular-first approach.
The TASC II guidelines were roundly criticized for the inclu-
sion of many lesions in the C and D classes that could be ap-
proached endovascularly. Such is the risk of putting out lesion
classification systems in a decade of such rapid improvements in
endovascular techniques and widespread adoption of same. A
proposed revised lesion scoring system would adjust all the lesions
(aortoiliac, femoropopliteal, and a new tibial system) toward the
endovascular side of the ledger, with only a few anatomic cases
suggested as primary open surgery, with the vast majority of open
revascularization to follow endovascular failure. This proposal has
yet to be approved by all societies, as the actual data below the
inguinal ligament is not as strong as in the iliacs.
As such the TASC lesion system is really most beneficial as a
tool to compare anatomic arterial substrate and really corresponds
to the T portion of the TNM classification system in oncology. It
allows comparisons in registries, clinical trials, etc. Since the orig-
inal system commented on open vs endovascular success likeli-
hood, it has required revision over time as endovascular techniques
and tools improved – and also the lesion classification has been
contentious for the implications for clinical practice, which is really
not the intent of the system per se.
As time goes by, many of the classic teaching regarding the
limitations of endovascular approaches in the iliacs are fading.
There are secondary procedures, but the actual number is not
huge. There is device cost, but shorter hospital stays account for
that, and it is cost-effective. Indeed, with the current bed crunch in
most hospitals and patients in the emergency department waiting
for beds, adding to the inpatient load with more open aortic
procedures is hardly feasible.
The failure of iliac endovascular approaches also appears more
favorable than open surgery. Infection is a rare event. As opposed
to a graft limb occlusion, a failure of endovascular therapy in the
iliacs appears less likely to embolize and lead to acute limb ischemiaenjoyed the paper. It is well written and the analysis is very clear.
o close, I have several questions for the authors:
First, my personal observations above aside, do the authors
ave an opinion regarding the outcome of endovascular failure
fter reviewing the records. Do patients who fail endovascular iliac
ntervention present with acute limb ischemia?
Dr Rachel C. Danczyk. Thank you for your thought-provok-
ng comments and interesting question. First, we know that 20% of
hose patients presenting with claudication progress to critical limb
schemia (CLI) after endovascular failure. The number of patients
ith acute limb ischemia, specifically, in this group is quite small,
ith only eight patients presenting with acute ischemia after fail-
re. The majority of patients who presented with progression to
LI experienced rest pain, followed by ulcers, and finally with
cute ischemia.
Dr Nehler. Second, the number of patients with concomitant
istal bypasses was not given in the results. Does having a distal
evascularization dependent on revascularized inflow affect the ap-
roach to endovascular therapy in the aortoiliac segment proximally?
Dr Danczyk. At the time of initial percutaneous transluminal
ngioplasty and stenting (PTAS), 44 patients underwent lower
xtremity bypass operations. In general, the best operative ap-
roach is applied to each patient and if inflow can be established
ith aortoiliac artery stenting, even if a distal bypass is anticipated,
hen an endovascular approach to aortoiliac occlusive disease
AIOD) is pursued. Therefore, having a distal bypass dependent
n revascularized inflow does not affect the approach to endovas-
ular therapy in the aortoiliac artery segment.
Dr Nehler. Third, what if any role does surveillance have in
hese procedures?
DrDanczyk.We do not currently have a surveillance protocol
or iliac stent patients like we do for those with bypass grafts. In
eneral, patients are followed with attention paid to clinical symp-
oms and ankle-brachial indexes (ABIs). Since iliac artery stents are
ot intervened upon prophylactically, we do not utilize a surveil-
ance protocol.
Dr Nehler. The number of patients with concomitant distal
ypasses was not given in the results. Does having a distal revascu-
arization dependent on revascularized inflow affect the approach
o endovascular therapy in the aortoiliac segment proximally?
Dr Danczyk. At the time of initial PTAS, 44 patients under-
ent lower extremity bypass operations. In general, the best oper-
tive approach is applied to each patient and if inflow can be
stablished with aortoiliac artery stenting, even if a distal bypass is
nticipated, then an endovascular approach to AIOD is pursued.
herefore, having a distal bypass dependent on revascularized
nflow does not affect the approach to endovascular therapy in the
ortoiliac artery segment.
Dr Nehler. What if any role does surveillance have in these
rocedures?
DrDanczyk.We do not currently have a surveillance protocol
or iliac stent patients like we do for those with bypass grafts. In
eneral, patients are followed with attention paid to clinical symp-
oms and ABIs. Since iliac artery stents are not intervened upon
rophylactically, we do not utilize a surveillance protocol.
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Volume 55, Number 6 Danczyk et al 1646.e1bupplementary Table I (online only). A, Clinical
haracteristics of patient groups
ariablea
CIA or EIA stent
(n  368)
CIA and EIA stent
(n  123) P
ge, years 62.9  9.5 63.3  10.6 .67
emale 34 (9.2) 8 (6.5) .46
omorbidities
CAD 223 (60.6) 86 (69.9) .07
DM 131 (35.6) 48 (39.0) .52
Hypertension 294 (79.9) 103 (83.7) .43
Hyperlipidemia 233 (63.3) 81 (65.9) .67
CRI 36 (9.8) 12 (9.8) .99
Hemodialysis 9 (2.4) 3 (2.4) .99
Tobacco history 339 (92.1) 118 (95.9) .22
edications
Aspirin 219 (59.5) 91 (74.0) .01b
Warfarin 22 (6.0) 6 (4.9) .82
-Blocker 189 (51.4) 65 (52.8) .84
Clopidogrel 30 (8.2) 6 (4.9) .32
Statin 219 (59.5) 70 (56.9) .67
ndication
Claudication 220 (59.8) 71 (57.7) .75
CLI 148 (40.2) 52 (42.3) .75
Rest pain 48 (13.0) 25 (20.3) .06
Gangrene 19 (5.2) 5 (4.1) .81
Ulcer 47 (12.8) 15 (12.2) .99
Acute ischemia 24 (6.5) 5 (4.1) .38
Unknown 8 (1.0) 0 (0.0) .99
AD, Coronary artery disease; CIA, common iliac artery, CLI, critical limb
schemia; CRI, chronic renal insufficiency (creatinine 1.5 mg/dL); DM,
iabetes mellitus; EIA, external iliac artery.
Continuous data are expressed as mean standard deviation; categoric data
s number (%).
Statistically significant (P  .05), 2 test/Fisher exact test.
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Variablea
CIA Stents
(n  299)
EIA or CIA  EIA stents
(n  289) P
Age, years 61.9  9.1 64.1  10.4 .01b
Female 37 (12.4) 21 (7.3) .04b
Comorbidities
CAD 181 (60.5) 194 (67.1) .10b
DM 119 (39.8) 105 (36.3) .40
Hypertension 235 (78.6) 241 (83.4) .14
Hyperlipidemia 196 (65.6) 179 (61.9) .39
CRI 45 (15.1) 28 (9.7) .06
Hemodialysis 13 (4.3) 4 (1.4) .05
Tobacco history 269 (90.0) 267 (92.4) .31
Medications
Aspirin 186 (62.2) 187 (64.7) .55
Warfarin 16 (5.4) 28 (9.7) .06
-Blocker 154 (51.5) 154 (53.3) .68
Clopidogrel 25 (8.4) 19 (6.6) .44
Statin 184 (61.5) 155 (53.6) .06
Indication
Claudication 171 (58.8) 136 (47.1) .01b
CLI 120 (41.2) 153 (52.9) .01b
Rest pain 36 (12.4) 59 (20.4) .01b
Gangrene 24 (8.2) 24 (8.3) .99
Ulcer 31 (10.7) 47 (16.3) .05
Acute ischemia 20 (6.9) 19 (6.6) .99
Unknown 8 (2.6) 0 (0.0) .99
CAD,Coronary artery disease;CIA, common iliac artery;CLI, critical limb ischemia;CRI, chronic renal insufficiency (creatinine1.5 mg/dL);DM, diabetes
mellitus; EIA, external iliac artery.
aContinuous data expressed as mean  standard deviation; categoric data as number (%).
bStatistically significant (P  .05), 2 test/Fisher exact test.
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ASupplementary Table II (online only). A, Clinical
outcomes of common iliac artery (CIA) or external iliac
artery (EIA) stent vs CIA and EIA stent groups
Outcome
CIA or
EIA stent
(n  368)
No (%)
CIA and EIA
stent (n123)
No. (%) Pa
Lost to follow-up 66 (17.9) 24 (19.5) .69
Death 110 (29.9) 35 (28.5) .82
SEI 61 (16.6) 18 (14.6) .67
Late open
conversion
29 (7.9) 10 (8.1) .99
Amputation 8 (2.2) 7 (5.7) .12SEI, Secondary endovascular intervention.
a2 test/Fisher exact test.
Supplementary Table II (online only). B, Clinical
utcomes of common iliac artery (CIA) stents group vs
xternal iliac artery (EIA) or CIA and EIA stents group
utcome
CIA Stents
(n  299)
No. (%)
EIA or CIA 
EIA Stents
(n  289)
No. (%) P
ost to follow-up 56 (18.7) 58 (20.1) .75
eath 83 (27.8) 100 (34.6) .08
EI 57 (19.1) 38 (13.1) .06
ate open
conversion
26 (8.7) 22 (7.6) .65
mputation 7 (2.3) 11 (3.8) .46EI, Secondary endovascular intervention.
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open conversion
Outcomea
Death SEI Late open conversion
(n  143) P (n  78) P (n  39) P
Age at PTAS, years 66.7  8.6 60.0  8.4 56.0  8.2
Female 4 (2.8) .01b 9 (11.4) .38 7 (17.9) .07
Comorbidities
CAD 108 (74.5) .01b 50 (63.3) .99 25 (64.1) .99
DM 66 (45.5) .01b 25 (31.6) .37 10 (25.6) .17
Hypertension 123 (84.8) .17 63 (79.7) .76 27 (69.2) .09
Hyperlipemia 87 (60.0) .26 47 (59.5) .37 25 (64.1) .99
CRI 25 (17.2) .01b 5 (6.3) .31 2 (5.1) .41
Hemodialysis 7 (4.8) .05 1 (1.3) .70 1 (2.6) .99
Tobacco history 132 (91.0) .25 78 (98.7) .03b 37 (94.9) .99
Medication
Aspirin 94 (64.8) .68 43 (54.4) .10 27 (69.2) .49
Warfarin 12 (8.3) .14 3 (3.8) .60 0 (0.0) .15
-Blocker 79 (54.5) .49 39 (49.4) .71 18 (46.2) .51
Clopidogrel 8 (5.5) .35 6 (7.6) .99 2 (5.1) .76
Statin 75 (51.7) .04b 43 (54.4) .39 22 (56.4) .74
Indication
CLI 84 (57.2) .01b 30 (38.0) .62 13 (33.3) .40
Acute ischemia 10 (6.9) .54 5 (6.3) .80 6 (15.4) .02b
Stent location
CIA or EIA 110 (75.9) .82 61 (77.2) .67 29 (74.4) .99
CIA and EIA 35 (24.1) 18 (22.8) 10 (25.6)
CAD, Coronary artery disease; CIA, common iliac artery; CLI, critical limb ischemia; CRI, chronic renal insufficiency (creatinine1.5 mg/dL); DM, diabetes
mellitus; EIA, external iliac artery; PTAS, percutaneous transarterial angioplasty and stenting; SEI, secondary endovascular intervention.
aContinuous data are presented as mean  standard deviation; categoric data are presented as number (%).
bStatistically significant (P  .05), 2 test/Fisher exact.
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open conversion
Variablea
Outcome
Death SEI Late open conversion
(n  183) P (n  95) P (n  48) P
Age at PTAS, years 66.9  8.5 59.8  8.1 57.2  8.8
Female 8 (4.4) .01b 12 (12.6) .35 9 (18.8) .04b
Comorbidities
CAD 138 (75.4) .01b 61 (64.2) .99 31 (64.6) .99
DM 85 (46.4) .03b 31 (32.6) .25 12 (25.0) .06
Hypertension 159 (86.9) .02b 72 (75.8) .20 32 (66.7) .01b
Hyperlipidemia 113 (61.7) .52 57 (60.0) .42 29 (60.4) .64
CRI 38 (20.8) .01b 6 (6.3) .06 2 (4.2) .11
Hemodialysis 11 (6.0) .01b 1 (1.1) .33 1 (2.1) .99
Tobacco history 159 (86.9) .02b 93 (97.9) .01b 44 (91.7) .99
Medication
Aspirin 120 (65.6) .52 55 (57.9) .25 34 (70.8) .35
Warfarin 20 (10.9) .04b 3 (3.2) .09 1 (2.1) .25
-Blocker 101 (55.2) .37 49 (51.6) .91 21 (43.8) .23
Clopidogrel 11 (6.0) .40 9 (9.5) .40 2 (4.2) .57
Statin 96 (52.5) .09 55 (57.9) .99 26 (54.2) .65
Indication
CLI 114 (62.3) .01b 37 (38.9) .42 19 (39.6) .36
Acute ischemia 14 (7.7) .59 6 (6.3) .99 7 (14.6) .03b
Stent location
CIA 83 (45.4) .08 57 (60.0) .06 26 (54.2) .65
EIA or CIA  EIA 100 (54.6) 38 (40.0) 22 (45.8)
CAD, Coronary artery disease; CIA, common iliac artery; CLI, critical limb ischemia; CRI, chronic renal insufficiency (creatinine1.5 mg/dL); DM, diabetes
mellitus; EIA, external iliac artery; PTAS, percutaneous transarterial angioplasty and stenting; SEI, secondary endovascular intervention.
aContinuous data are presented as mean  standard deviation; categoric data as number (%).
bStatistically significant (P  .05), 2 test/Fisher exact test.Supplementary Table IV (online only). A, Cox regression of death, secondary endovascular intervention, and late
open conversion
Variable
Outcome
Death (n  143) SEI (n  78) Late open conversion (n  39)
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Female 0.34 (0.12-0.93) .04 1.60 (0.78-3.33) .20 1.85 (0.77-4.47) .17
Comorbidities
CAD 1.85 (1.20-2.85) .01a 1.09 (0.66-1.79) .75 1.47 (0.70-3.07) .31
DM 1.29 (0.90-1.85) .17 0.84 (0.50-1.39) .49 0.65 (0.30-1.41) .28
Hypertension 1.06 (0.61-1.84) .85 0.78 (0.41-1.50) .46 0.51 (0.21-1.22) .13
Hyperlipidemia 0.94 (0.59-1.50) .80 0.65 (0.35-1.22) .18 0.90 (0.38-2.16) .90
Tobacco history 0.40 (0.21-0.76) .01a 7.63 (1.04-56.07) .05 1.00 (0.23-4.40) .99
Medication
Aspirin 1.31 (0.90-1.94) .17 0.69 (0.41-1.14) .14 1.47 (0.69-3.13) .32
-Blocker 1.18 (0.80-1.74) .40 1.33 (0.78-2.28) .29 1.04 (0.48-2.27) .92
Statin 0.59 (0.37-0.93) .02a 1.06 (0.57-1.97) .85 1.15 (0.49-2.71) .74
Indication
CLI 2.27 (1.59-3.23) .01a 1.36 (0.83-2.24) .22 1.24 (0.60-2.57) .56
Stent location
CIA and EIA 1.32 (0.88-1.98) .19 1.39 (0.78-2.47) .27 1.06 (0.50-2.26) .87
CAD, Coronary artery disease; CI, confidence interval; CIA, common iliac artery; CLI, critical limb ischemia; DM, diabetes mellitus; EIA, external iliac artery;
HR, hazard ratio; SEI, secondary endovascular intervention.
aStatistically significant (P  .05), forced entry.
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Volume 55, Number 6 Danczyk et al 1646.e5Supplementary Table IV (online only). B, Cox regression of death, secondary endovascular intervention, and late
open conversion
Variable
Outcome
Death (n  183) SEI (n  95)
Late open conversion
(n  48)
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Female 0.35 (0.13-0.97) .04a 1.58 (0.77-3.28) .22 1.74 (0.71-4.25) .23
Comorbidities
CAD 1.87 (1.22-2.88) .01a 1.10 (0.66-1.82) .72 1.56 (0.73-3.30) .25
DM 1.26 (0.89-1.80) .20 0.82 (0.49-1.36) .44 0.65 (0.30-1.40) .27
Hypertension 1.07 (0.61-1.86) .82 0.78 (0.41-1.50) .46 0.54 (0.22-1.29) .16
Hyperlipidemia 0.92 (0.58-1.47) .73 0.64 (0.34-1.20) .16 0.84 (0.35-2.01) .69
Tobacco history 0.39 (0.21-0.74) .01a 7.30 (0.99-53.70) .05 0.92 (0.21-4.05) .91
Medication
Aspirin 1.24 (0.84-1.83) .28 0.65 (0.40-1.07) .09 1.47 (0.69-3.11) .32
-Blocker 1.23 (0.83-1.82) .30 1.36 (0.79-2.32) .27 0.99 (0.45-2.16) .98
Statin 0.58 (0.36-0.91) .02a 1.08 (0.58-2.02) .81 1.23 (0.52-2.91) .64
Indication
CLI 2.23 (1.57-3.17) .01a 1.38 (0.84-2.27) .20 1.26 (0.61-2.63) .53
Stent location
EIA or CIA  EIA 0.95 (0.68-1.33) .77 0.88 (0.55-1.41) .58 0.79 (0.40-1.57) .50
CAD, Coronary artery disease; CI, confidence interval; CIA, common iliac artery; CLI, critical limb ischemia; DM, diabetes mellitus; EIA, external iliac artery;
HR, hazard ratio; SEI, secondary endovascular intervention.
aStatistically significant (P  .05), forced entry.
